Bausch + Lomb Corporation BLCO
Set alert
At close · Oct 30
After hours · Oct 30, 5:05 PM ET
- YTD
- +17.10%
- 1 year
- +32.10%
- Open
- 20.85
- Prev close
- 20.40
- Mkt cap
- 7.15B
- Vol
- 1.43M
- Avg vol
- 539.72K
- EPS
- -0.32
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 19.83
- High
- 20.85
- Forward P/E
- 16.72
- Beta
- 0.00
- Short ratio
- 5.12
- Inst. own
- 11.24%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 17, 2027
- 50-d avg
- 17.29
- 200-d avg
- 16.66
- 1y target
- 21.64
5D chart
Events in this range
- Oct 28, 2026Earnings: 0.34; estimate 0.2145; surprise 58.51%
- Oct 29, 2026Rating: Wells Fargo · Equal-Weight → Equal-Weight
- Oct 29, 2026Rating: RBC Capital · Outperform → Outperform
- Oct 29, 2026Rating: Citigroup · Buy → Buy
- Oct 29, 2026Rating: JP Morgan · Neutral → Neutral
Signals (109)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 11:10 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:00 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:50 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:50 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:45 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:45 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:10 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:00 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:00 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:55 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:50 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 4:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:35 PM | 3 days ago |
| RSI: Oversold | Oct 29, 3:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:10 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:15 AM | 3 days ago |
| RSI: Overbought | Oct 28, 3:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 4 days ago |
| RSI: Overbought | Oct 28, 3:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:45 PM | 4 days ago |
| RSI: Overbought | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:15 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:50 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:10 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:45 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:45 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:30 AM | 4 days ago |
| RSI: Oversold | Oct 27, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:25 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 11:50 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 11:25 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:10 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| RSI: Oversold | Oct 27, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:35 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:25 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:05 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 12:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:55 AM | 6 days ago |
News
-
3 days ago benzinga.com
JP Morgan Maintains Neutral on Bausch & Lomb, Raises Price Target to $22
JP Morgan analyst Robbie Marcus maintains Bausch & Lomb (NYSE:BLCO) with a Neutral and raises the price target from $16 to $22.
-
3 days ago benzinga.com
RBC Capital Maintains Outperform on Bausch & Lomb, Raises Price Target to $23
RBC Capital analyst Douglas Miehm maintains Bausch & Lomb (NYSE:BLCO) with a Outperform and raises the price target from $21 to $23.
-
3 days ago benzinga.com
Wells Fargo Maintains Equal-Weight on Bausch & Lomb, Raises Price Target to $19
Wells Fargo analyst Larry Biegelsen maintains Bausch & Lomb (NYSE:BLCO) with a Equal-Weight and raises the price target from $18 to $19.
3 days ago businesswire.com
Bausch + Lomb Announces Publication of Multinational Survey Results Highlighting the Burden of Dry Eye Symptoms and Opportunities for Improved Awareness and Patient Education
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the…
3 days ago marketbeat.com
What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Call
Bausch + Lomb NYSE: BLCO reported third-quarter revenue growth across all three business segments, raised its full-year outlook for the third time in 2026 and highlighted continued margin expansion…
4 days ago seekingalpha.com
Bausch + Lomb Corporation (BLCO) Q3 2026 Earnings Call Transcript
Bausch + Lomb Corporation (BLCO) Q3 2026 Earnings Call Transcript
4 days ago zacks.com
Bausch + Lomb (BLCO) Surpasses Q3 Earnings and Revenue Estimates
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.18 per share a year ago.
-
4 days ago benzinga.com
Bausch & Lomb Q3 Adj. EPS $0.34 Beats $0.22 Estimate, Sales $1.375B Beat $1.373B Estimate
Bausch & Lomb (NYSE:BLCO) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.22 by 54.55 percent. This is a 88.89 percent increase over earnings of $0.18…
-
4 days ago benzinga.com
Bausch & Lomb Raises FY2026 Sales Guidance from $5.440B-$5.540B to $5.450B-$5.550B vs $5.496B Est
Bausch & Lomb (NYSE:BLCO) raises FY2026 sales outlook from $5.440 billion-$5.540 billion to $5.450 billion-$5.550 billion vs $5.496 billion estimate.
4 days ago businesswire.com
Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its…
1 week ago benzinga.com
Billionaire Investor Took a Stake in Bausch + Lomb Before Its CEO Shake-Up
Dan Loeb’s Third Point acquired approximately 85,000 Bausch + Lomb shares worth about $1.4 million as of June 30, according to the filing.
2 weeks ago benzinga.com
Why Is Bausch + Lomb Stock Falling Monday?
Bausch + Lomb stock drops 10% following sudden CEO departure, despite raising full-year 2026 EBITDA guidance.
2 weeks ago defenseworld.net
Bausch + Lomb (NYSE:BLCO) Shares Down 5.8% – What’s Next?
Bausch + Lomb Corporation (NYSE: BLCO - Get Free Report)'s stock price fell 5.8% during mid-day trading on Monday. The company traded as low as $16.13 and last traded at $16.2990. Approximately…
-
2 weeks ago benzinga.com
Bausch + Lomb Appoints Chairman Thomas J. Appio As Interim CEO, Effective Immediately; Company And Its Parent Bausch Health Expect To Raise FY26 Adjusted EBITDA Guidance, Excluding Acquired IPR&D
Preliminary Update on 2026 Guidance2Based on preliminary third-quarter results, Bausch + Lomb and Bausch Health currently expect to raise full-year 2026 adjusted EBITDA excluding Acquired IPR&D1…
2 weeks ago businesswire.com
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today…
3 weeks ago businesswire.com
Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced progress in…
3 weeks ago businesswire.com
Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its…
4 weeks ago defenseworld.net
Head to Head Survey: Bausch + Lomb (NYSE:BLCO) vs. Terumo (OTCMKTS:TRUMY)
Terumo (OTCMKTS:TRUMY - Get Free Report) and Bausch + Lomb (NYSE: BLCO - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the…
1 month ago defenseworld.net
Financial Survey: Merit Medical Systems (NASDAQ:MMSI) vs. Bausch + Lomb (NYSE:BLCO)
Merit Medical Systems (NASDAQ: MMSI - Get Free Report) and Bausch + Lomb (NYSE: BLCO - Get Free Report) are both mid-cap healthcare companies, but which is the superior investment? We will compare…
1 month ago benzinga.com
‘Crisis of Its Own Creation’: Activist JANA Blasts Cooper, Demands CEO Search
Activist firm Jana Partners calls for leadership overhaul and asset sales at Cooper Companies (COO) amid governance concerns.
1 month ago zacks.com
BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser
Bausch + Lomb gains European CE Mark approval for SeeLyra, expanding its surgical portfolio with a compact laser platform for cataract and corneal procedures.
1 month ago businesswire.com
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European CE…
-
1 month ago benzinga.com
Leerink Partners Initiates Coverage On Bausch & Lomb with Outperform Rating, Announces Price Target of $24
Leerink Partners analyst Daniel Clark initiates coverage on Bausch & Lomb (NYSE:BLCO) with a Outperform rating and announces Price Target of $24.
2 months ago businesswire.com
Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the…
2 months ago businesswire.com
Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced findings from…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Bausch & Lomb, Maintains $21 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Bausch & Lomb (NYSE:BLCO) with a Buy and maintains $21 price target.
2 months ago zacks.com
Bausch + Lomb Advances Two First-in-Class Eye Health Therapies
BLCO advances two eye-health candidates after positive trial results, with combined estimated peak sales exceeding $2 billion.
2 months ago benzinga.com
Bausch + Lomb Advances Two Eye Therapies With Blockbuster Sales Potential
Bausch + Lomb (NYSE: BLCO) advances two first-in-class eye drugs to advanced clinical testing, eyeing $2B+ in peak sales.
2 months ago seekingalpha.com
Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript
Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript
2 months ago marketbeat.com
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal
Bausch + Lomb NYSE: BLCO said it plans to advance a dual-action dry eye treatment into Phase III development after a Phase II study showed statistically significant improvement in corneal staining at…
2 months ago benzinga.com
Carl Icahn Trims JetBlue, AEP Stakes While Sitting Out New Stock Bets
Carl Icahn made no new stock purchases in Q2, trimming stakes in JetBlue and American Electric Power. The rest of his portfolio is unchanged.
2 months ago fool.com
Insider Sheds Nearly 53,000 Shares of Consumer Health Stock, Valued at Almost $900,000
Liquidation represents 54% of insider's direct equity stake, executed at $16.78 per share following a 23% stock gain over 12 months.
2 months ago prnewswire.com
Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board
LAVAL, QC, Aug. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company"), today announced that its CEO, Thomas J. Appio, has been appointed to the…
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Bausch & Lomb, Raises Price Target to $21
HC Wainwright & Co. analyst Yi Chen maintains Bausch & Lomb (NYSE:BLCO) with a Buy and raises the price target from $20 to $21.
-
3 months ago benzinga.com
UBS Maintains Buy on Bausch & Lomb, Raises Price Target to $23
UBS analyst Patrick Wood maintains Bausch & Lomb (NYSE:BLCO) with a Buy and raises the price target from $21 to $23.
-
3 months ago benzinga.com
Bausch & Lomb Q2 Adj. EPS $0.16 Beats $0.15 Estimate, Sales $1.394B Beat $1.369B Estimate
Bausch & Lomb (NYSE:BLCO) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.15 by 6.67 percent. This is a 128.57 percent increase over earnings of $0.07…
-
3 months ago benzinga.com
Bausch & Lomb Raises FY2026 Sales Guidance from $5.420B-$5.520B to $5.440B-$5.540B vs $5.468B Est
Bausch & Lomb (NYSE:BLCO) raises FY2026 sales outlook from $5.420 billion-$5.520 billion to $5.440 billion-$5.540 billion vs $5.468 billion estimate.
-
3 months ago benzinga.com
UBS Initiates Coverage On Bausch & Lomb with Buy Rating, Announces Price Target of $21
UBS analyst Patrick Wood initiates coverage on Bausch & Lomb (NYSE:BLCO) with a Buy rating and announces Price Target of $21.
-
3 months ago benzinga.com
Bausch + Lomb Announces U.S. Launch Of EyeGility Inserter Preloaded IOL Delivery System
EyeGility is designed for the enVista® family of IOLsOffers balanced push force for smooth delivery, convenient one-handed operationAvailable now for enVista Aspire™; will be available for enVista…
3 months ago benzinga.com
Bausch + Lomb Ends Glaucoma Drug Development, Shifts Focus
Bausch + Lomb ended BL1107 glaucoma eye drop development after a Phase 2 miss and will focus on a sustained-release GA implant.
-
3 months ago benzinga.com
Bausch + Lomb Announces Phase 2 Topline Results For BL1107 In Glaucoma; Study Did Not Meet Primary Endpoint Of Replicating Earlier Visual Gains, And Company Will Discontinue Development As Topical Eye Drop
Phase 2 study did not meet its primary endpoint.Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the…
-
3 months ago benzinga.com
Bausch + Lomb Creates Orphia, New AI-Powered Digital Health Platform
Designed to reduce the operational burden that stands between physicians and their patients.Initial offering focuses on pre-surgery cataract education, with additional AI capabilities for…
-
3 months ago benzinga.com
Evercore ISI Group Maintains In-Line on Bausch & Lomb, Raises Price Target to $17
Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a In-Line and raises the price target from $16 to $17.
-
6 months ago benzinga.com
Evercore ISI Group Maintains In-Line on Bausch & Lomb, Lowers Price Target to $16
Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a In-Line and lowers the price target from $17 to $16.
-
6 months ago benzinga.com
Bausch & Lomb Raises FY2026 Sales Guidance from $5.375B-$5.475B to $5.420B-$5.520B vs $5.436B Est
Bausch & Lomb (NYSE:BLCO) raises FY2026 sales outlook from $5.375 billion-$5.475 billion to $5.420 billion-$5.520 billion vs $5.436 billion estimate.
6 months ago benzinga.com
Earnings Scheduled For April 29, 2026
Earnings Scheduled For April 29, 2026
-
6 months ago benzinga.com
Bausch & Lomb Q1 Adj. EPS $0.08 Beats $0.06 Estimate, Sales $1.244B Beat $1.218B Estimate
Bausch & Lomb (NYSE:BLCO) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.06 by 33.33 percent. This is a 214.29 percent increase over losses of $(0.07)…
-
6 months ago benzinga.com
Bausch + Lomb Announces European Commercial Availability Of Preloaded enVista Envy Full Range Of Vision Intraocular Lens
enVista Envy is the first diffractive premium IOL from Bausch + Lomb available in EuropeOffers a continuous range of vision with excellent dysphotopsia toleranceEyeGility™ delivery system contributes…
-
6 months ago benzinga.com
Evercore ISI Group Maintains In-Line on Bausch & Lomb, Lowers Price Target to $17
Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a In-Line and lowers the price target from $17.5 to $17.
-
6 months ago benzinga.com
Bausch + Lomb To Highlight Results Of Studies Evaluating Portfolio Of Products, Including ELIOS MIGS System, enVista Envy Full Visual Range And enVista Aspire IOLs, MIEBO, ScoutPro Point-Of-Care Osmolarity Testing Device, Stellaris Elite Vision Enhancement System, TENEO Excimer Laser Platform And XIIDRA 5% At ASCRS Annual Meeting
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of new scientific data and events…